(Accesswire — September 28, 2017) CV Sciences, Inc. (CVSI) (the “Company,” “CV Sciences,” “our” or “we”), market-leading supplier and manufacturer of hemp-derived cannabidiol (CBD) products and developer of specialty pharmaceutical therapeutics, will be presenting at this year’s MicroCap Conference on October 5th in New York City.
Joseph Dowling, Chief Financial Officer of CV Sciences, Inc. will be delivering a presentation to attendees providing details about our lead drug candidate, CVSI-007, which utilizes synthetically-formulated CBD for the treatment of smokeless tobacco addiction. In addition, Mr. Dowling will discuss the Company’s success within its consumer CBD products division, review recent Company highlights and be available for one-on-one meetings. To arrange a one-on-one meeting with management, please contact Robert Haag at CVSI@irthcommunications.com or 866-976-4784.
Please use the following link for the Webcast: http://wsw.com/webcast/microcapconf5/cvsi/
CONFERENCE OVERVIEW AND STRUCTURE
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.
The MicroCap Conference will take place in New York City at the Essex House on October 5th. Registration will begin on Thursday at 7:00AM, and will last until the evening. The Conference will be jam-packed with company sessions, presentations, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers — only portfolio managers, analysts, and private investors.
REGISTRATION FOR INVESTORS
To register, please visit The MicroCap Conference website (microcapconf.com/conferences/new-york-2-2017/), and click “Investor Registration.”
For our most updated list of companies, please go to The MicroCap Conference website (microcapconf.com/conferences/new-york-2-2017/).
The Special Equities Group
Wexler Burkhart Hirschberg & Unger
PCG Advisory Group
About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
News Compliments of ACCESSWIRE.
FOR MORE INFORMATION
Please visit: www.microcapconf.com
Or, contact Tony Yu at firstname.lastname@example.org